Inhibikase Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Inhibikase Therapeutics

13/05/2023 01:26

* Inhibikase Therapeutics Inc  IKT.OQ   IKT.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 15. 
    * 
    * ​Refinitiv's mean analyst estimate for Inhibikase
Therapeutics
Inc is for a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $5​, above​ its last closing price of $0.61.
​​​

This summary was machine generated May 13 at 00:26 GMT.  All
figures in US dollars  unless otherwise stated